Neurobiological Technologies, Inc. NTII

NTII Company Overview

Neurobiological Technologies, Inc. (NTII) was a U.S.-based biopharmaceutical company focused on the research and development of therapies for neurological and vascular disorders, particularly acute ischemic stroke and other conditions involving the central nervous system. The company operated within the biotechnology and pharmaceutical industries and was primarily engaged in clinical-stage drug development rather than large-scale commercial manufacturing or diversified healthcare operations. Public filings and historical market records indicate that NTII’s principal value driver was its lead drug candidate, Viprinex (ancrod), a fibrinolytic agent derived from Malayan pit viper venom that was investigated as a treatment for acute ischemic stroke.

The company was founded in the late 1980s and was headquartered in Emeryville, California. Over time, NTII evolved from a neuroscience-focused biotechnology research enterprise into a more concentrated clinical development company centered on stroke therapeutics. Its strategic positioning relied heavily on proprietary drug development and partnerships with larger pharmaceutical organizations for commercialization and distribution capabilities. Historical reporting indicates that the company faced substantial clinical and financial challenges after setbacks in late-stage trials, and publicly available records suggest that operations were significantly reduced following the discontinuation of key development programs. Data regarding the company’s current operating status is inconclusive based on available public sources.